CRISPR Therapeutics (CRSP)
(Real Time Quote from BATS)
$55.24 USD
-0.49 (-0.88%)
Updated May 24, 2024 03:48 PM ET
After-Market: $55.25 +0.01 (0.02%) 4:06 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$55.24 USD
-0.49 (-0.88%)
Updated May 24, 2024 03:48 PM ET
After-Market: $55.25 +0.01 (0.02%) 4:06 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Zacks News
3 Strong Pharmaceutical and Biotech Stocks to Buy for Coronavirus Immunity
by Benjamin Rains
Let's dive into three large-cap pharmaceutical and biotech stocks that appear set to grow during the pandemic-induced downturn and the eventual recovery...
Why Is CRISPR Therapeutics AG (CRSP) Up 22.9% Since Last Earnings Report?
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bull of the Day: Vertex Pharma (VRTX)
by Kevin Cook
While COVID-19 interrupts clinical trials, the champ of cystic fibrosis is about to repeat another year of 37% revenue growth
Chart Radar: Buy Software, Sell Banks
by Kevin Cook
If a bigger pullback is unfolding in this over-valued market, now is the time to plan your big dip buys.
Vertex (VRTX) Q1 Earnings Beat, Trikafta Drives CF Revenues
by Zacks Equity Research
Vertex (VRTX) rides high on earnings and revenue beat in Q1.The company raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -5.50% and -97.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate CRISPR Therapeutics AG (CRSP) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes CRISPR Therapeutics AG (CRSP) a New Buy Stock
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $39.54, moving +1.49% from the previous trading session.
CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed at $44.67 in the latest trading session, marking a +0.84% move from the prior day.
What's in Store for Vertex in 2020 After a Remarkable 2019?
by Kinjel Shah
In 2020, Vertex's (VRTX) sales are expected to be primarily driven by Trikafta and higher international revenues.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed at $54.33 in the latest trading session, marking a -0.93% move from the prior day.
Expand Your Portfolio with this First Profit Stock Screener
by Benjamin Rains
We are in the midst of the fourth quarter earnings season. This makes it a great time to use our 'First Profit' stock screener. The idea is to search for companies that recently reported their first quarterly profit...
CRISPR Therapeutics AG (CRSP) Stock Moves -0.9%: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed at $51.95 in the latest trading session, marking a -0.9% move from the prior day.
Vertex (VRTX) Q4 Earnings Beat on Solid CF Product Sales
by Zacks Equity Research
Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.
Can CF Drugs Drive Growth for Vertex (VRTX) in Q4 Earnings?
by Zacks Equity Research
On Vertex's (VRTX) fourth-quarter earnings call, investor focus will be on the sales uptake of its CF drugs and the unveiling plans for the newly-approved Trikafta triple combination regimen.
SCANS: The FAANG of The Roaring 20s
by Daniel Laboe
A new acronym of equities that could define the next decade of investing.
The Zacks Analyst Blog Highlights: Sea Limited, CRISPR, Alibaba, Nvidia and Splunk
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Sea Limited, CRISPR, Alibaba, Nvidia and Splunk
SCANS: The FAANG Of The Roaring 20s
by Daniel Laboe
I have chosen a new acronym of stocks that I believe could change the world in the roaring 20s
CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed at $59.44 in the latest trading session, marking a +0.2% move from the prior day.
What the Tech?
by Panel Of Zacks Experts
Let's REALLY dive deep into the abyss which can be tech. Associate Stock Strategist Dan Laboe, Zacks' resident Tech geek joins us.
Find Strong Stocks Heading into 2020 with this First Profit Screen
by Benjamin Rains
Wall Street has started to look ahead to 2020. So today we are going to use our 'First Profit' stock screen to help investors find strong stocks heading into the new year...
Trade of the 2020's: Sell Gold, Buy Biotech
by Kevin Cook
In 5 years, you be selling your gold and buying more companies leading the century of biology.
Biotech Tops in November: Best ETFs & Stocks
by Sweta Killa
The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.
The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG
by Zacks Equity Research
The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG